Welcome to our dedicated page for APNW news (Ticker: APNW), a resource for investors and traders seeking the latest updates and insights on APNW stock.
Apeiron Capital Investment Corp. (APNW) is a blank check company established with the goal of executing a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. As a special purpose acquisition company (SPAC), Apeiron Capital Investment Corp. aims to leverage its management's expertise to identify and integrate promising business ventures.
The company, headed by CEO Dr. Joel Shulman, recently announced the termination of its Business Combination Agreement with GIO World Health, Ltd., effective August 14, 2023. This agreement was initially formed on March 8, 2023, and amended on May 10, 2023. The termination comes as a result of the company’s inability to finalize an initial business combination within the stipulated timeframe mandated by its Amended and Restated Certificate of Incorporation.
With the termination finalized, Apeiron Capital Investment Corp. intends to dissolve and liquidate, redeeming all outstanding shares of common stock included in the units issued to public stockholders during its initial public offering. The redemption price per share will reflect the aggregate funds in the company’s trust account, including interest, minus dissolution expenses. Shareholders are expected to receive their pro rata portion of the trust account proceeds within ten business days post-August 14, 2023.
The company’s sponsor has agreed to waive redemption rights concerning its founder shares from a private placement, and there will be no redemption rights or liquidating distributions for the company's warrants, which are set to expire worthless.
This procedural liquidation underscores Apeiron Capital Investment Corp.'s commitment to ensuring the equitable treatment of its public shareholders. The company's operations have been closely monitored by regulatory authorities, including the SEC, as it navigates this complex financial landscape.
GIO World Health Ltd has announced a business combination agreement with Apeiron Capital Investment Corp (APNC) to take GIO public, valuing the company at a pre-money enterprise value of $250 million. Post-closing, current GIO shareholders will maintain 100% equity and approximately 80.83% ownership in the combined entity, which will be named GIO World Health Holdings, Inc. The transaction aims to provide a platform for GIO's stem cell treatments and other products. The deal is anticipated to close in the second half of 2023, pending shareholder approvals and customary conditions.
Apeiron Capital Investment Corp. (NYSE: APN U) announced on December 29, 2021, that starting December 30, holders of its IPO units can separately trade shares of Class A common stock (symbol: APN) and warrants (symbol: APN W). No fractional warrants will be issued upon separation, and the units that remain unseparated will continue trading under the symbol APN U. The Company is a blank check firm aiming for mergers or acquisitions, primarily in the financial technology, media, gaming, and wealth-advisory sectors.
Apeiron Capital Investment Corp. closed its IPO of 17,250,000 units at $10.00 each, including the full exercise of the underwriters' over-allotment option. The units began trading on the NYSE under the ticker symbol 'APNU' on November 9, 2021. Each unit comprises one share of Class A common stock and one-half of a redeemable warrant, with each whole warrant exercisable at $11.50 per share. The Company aims for business combinations mainly in financial technology, media, gaming, and wealth-advisory sectors.
Apeiron Capital Investment Corp. announced the pricing of its initial public offering (IPO) of 15,000,000 units at $10.00 per unit, set to begin trading on the NYSE under the ticker APN U on November 9, 2021. Each unit comprises one share of Class A common stock and one-half of a redeemable warrant, with whole warrants exercisable at $11.50 per share. The offering is expected to close on November 12, 2021, pending customary conditions. The company intends to focus on mergers in the FTMG sectors, while Cantor Fitzgerald serves as the offering manager.
FAQ
What is Apeiron Capital Investment Corp. (APNW)?
Who is the CEO of Apeiron Capital Investment Corp.?
Why did Apeiron Capital Investment Corp. terminate its agreement with GIO World Health, Ltd.?
What will happen to the public shares of Apeiron Capital Investment Corp.?
When will the redemption of public shares be completed?
Will the company's warrants be redeemed?
What steps are required to redeem public shares?
Where will the redemption funds be held prior to disbursement?
What does the term 'blank check company' mean?
What is the significance of the company’s Amended and Restated Certificate of Incorporation?
